Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.

Employees - 2, CEO - Bastiaan van der Baan, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -49.39, Piotroski Score(max is 10): 1, Working Capital: $1029599, Total Assets: $1514228, Retained Earnings: $-52777248, EBIT: -3308407, Total Liabilities: $355098, Revenue: $0

AryaFin Target Price - $0.46 - Current Price $ - Analyst Target Price $